Kate Bingham joined SV Health Investors in 1991 and is one of 5 MPs who manage seven venture capital funds and one public fund (>$2bn total assets) for life sciences investing in US and Europe. Kate is responsible for biotech investments and activities in the EU and serves/d on the boards of companies in the UK, US, Ireland, Sweden and Germany. Kate played an active role in setting up the new Dementia Discovery Fund (DDF). These investments include small molecule drug discovery and development projects, biotherapeutic development projects and drug discovery platforms in a broad range of clinical areas.
Prior to joining SVHI, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm. Kate has a first class degree in Biochemistry from Oxford University and graduated from Harvard Business School with an MBA (Baker Scholar).